



## PCSK9 Inhibitors: Kentucky

### PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs work by preventing the PCSK9 protein from destroying a receptor on the liver that clears bad cholesterol. The receptor “lives” longer, clearing more LDL cholesterol for the patient.

PCSK9 inhibitors are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

### Analysis of Health Plan Coverage & Access


A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Kentucky from August 6, 2015 to July 21, 2016.

#### Key Kentucky Findings



Rejection Rate:

**48%**



Total rejections:

**1,060**



Total appeals:

**285**

Of health plans that received at least 50 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

Kentucky Employees Health Plan **93%** | Anthem **71%**  
Wellcare Management Group **62%** | United Health Group **56%**

The following had **the lowest rates of rejection:**

Aetna US Healthcare **44%** | CVS Health **44%**  
Humana Health Plan **29%**

The following table details claims data for the Kentucky managed care organizations that received at least 50 claims for PCSK9 inhibitors.

MANAGED CARE ORGANIZATION	Rejection %	Total Claims	Approvals	Rejections	Reversals
Kentucky Employees Health Plan	93.15%	73	5	68	0
Anthem	71.88%	160	31	115	14
Wellcare Management Group	62.22%	90	29	56	5
United Health Group	56.94%	144	38	82	24
Express Scripts	55.76%	165	57	92	16
Cigna Healthcare	50.75%	67	28	34	5
CVS Health	44.75%	181	73	81	27
Aetna US Healthcare	44.53%	128	48	57	23
Humana Health Plan	29.85%	881	450	263	168

*Data source: National data supplier; Medicare, Medicaid managed care and commercial plans; August 6, 2015-July 21, 2016.*



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

